KEYLYNK 7339-010
Patient Summary

 

This clinical trial is for men who have metastatic castration resistant prostate cancer (mCRPC) and failed to respond abiraterone acetate or enzalutamide (but not both) and to chemotherapy. 

Why is this study being done?

This study is trying to find out if a combination of two investigational medications is safe and works to slow down or stop the growth of mCRPC compared to the standard of care. Researchers don’t know if these investigational medications work to treat this type of cancer.

The treatments being studied:

The treatments being studied are called Pembrolizumab and Olaparib. Pembrolizumab is a type of immunotherapy, which may help the body’s immune system attack cancer cells. This immunotherapy is FDA approved to treat other types of cancer but is not approved to treat mCRPC. Olaparib is a targeted therapy called a PARP inhibitor that may help limit a cancer cell’s ability to repair itself and can lead to death of the cancer cells. Before deciding to participate, you should make sure you understand the potential side effects or risks of participating in the study. These will be explained to you by the study doctor. If there is anything you do not understand; you are encouraged to ask the study doctor.

For more information, click here.

Organization: Merck

If you are interested in this trial, review the following:

Register your interest or comments about this trial with PHEN

PHEN Contact: 617-481-4020*

Please Note: This information is provided for education and awareness purposes. A decision on clinical trials participation is to be made between the patient and his doctor.
 

Go Back

 















PHEN,Inc. © 2019 All rights reserved